Jacobs Levy Equity Management, Inc Lyell Immunopharma, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,385,301 shares of LYEL stock, worth $845,033. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,385,301Holding current value
$845,033% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding LYEL
# of Institutions
107Shares Held
171MCall Options Held
7.7KPut Options Held
15.3K-
Mwg Management Ltd. Washington, DC20.2MShares$12.3 Million17.35% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$9.21 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$9.21 Million14.08% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$8.23 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA11.9MShares$7.26 Million1.63% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $151M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...